Biotechnology Analysts, along with Key Opinion Leader Dr. Hope Rugo, discuss the breast-cancer landscape and the outlook for Relay Therapeutics’ RLY-2608 on an Analyst/Industry conference call to be held on March 20 at 3 pm.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RLAY:
- Relay Therapeutics price target lowered to $28 from $45 at Guggenheim
- Relay Therapeutics price target raised to $46 from $43 at H.C. Wainwright
- Relay Therapeutics to Present Initial Clinical Data on RLY-2608 at AACR
- Relay Therapeutics to Participate in Two Upcoming Investor Conferences
- Relay Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Highlights
